Dr. Amit Raina provides expertise in pancreatic diseases at Mercy's Institute for Digestive Health and Liver Disease.
Mercy's team of top surgeons are known for their expertise in correcting ankle deformities caused by unsuccessful ankle fracture treatments.
Our Center offers physician expertise with a dedication to advancing services and treatments for neurological disorders and neuromuscular diseases.
Mercy offers emergency care on the Downtown Baltimore campus 24 hours a day, 7 days a week (410-332-9477) with access to a trained emergency medicine team, diagnostic services and consultations with specialists.
In case of an Emergency, Dial 911 and follow the instructions of the EMS (Emergency Medical Services) team.
Mercy Medical Center's downtown campus includes our Main Hospital - The Mary Catherine Bunting Center, McAuley Plaza and The Weinberg Center.
General visiting hours at Mercy are 11:00 am to 8:30 pm. Hours vary by floor, please check with the nursing staff or call 410-332-9555.
Currently Displaying: Active Clinical Trials; All Topics of Study
This study is a phase 3 trial evaluating the effect of obeticholic acid on clinical outcomes in patients with primary biliary cirrhosis.
The purpose of this research study is to evaluate effectiveness and safety of Lanreotide for treating neuroendocrine tumors (NET) of the lungs. (ClinicalTrials.gov ID#: NCT02683941)
This trial is an observational time and motion study in a clinical oncology setting to measure and compare product attributes and overall product efficiency between lanreotide and octreotide LAR. (Clinicaltrials.gov ID#: NCT03017690)
The purpose of this study is to compare 2 years of Palbociclib in combination with standard anti-hormone therapy to using standard anti-hormone therapy alone in patients with hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer. (Clinicaltrials.gov ID#: NCT02513394)
This is a phase III trial to determine how well cisplatin or carboplatin (platinum based chemotherapy) works compared to capecitabine in treating patients with triple-negative breast cancer who have residual disease following neoadjuvant chemotherapy and surgery. (Clinicaltrials.gov ID#: NCT02445391)
This study is designed for patients desiring nipple reconstruction following surgery for breast cancer and breast reconstruction. Eligible patients will receive a surgical procedure to reconstruct one or both nipples utilizing the COOK® Biodesign® Plastic Surgery Matrix. The study is designed to evaluate the benefit of this device in achieving effective and aesthetic nipple reconstruction. Patients will be evaluated at the time of the procedure and at 1 week, 4 weeks, 3 months, 6 months, and 12 months after surgery to examine the projection of their reconstructed nipple(s) and patient satisfaction (Cook Medical Study 09-009; Clinicaltrials.gov ID#: NCT01216319).
The purpose of this study is to compare the efficacy and safety of MPDL3280A versus standard of care in patients with Stage IB−Stage IIIA non-small cell lung cancer following resection and adjuvant chemotherapy. (Clinicaltrials.gov ID#: NCT02486718)
This study is researching the link between insulin resistance and breast cancer prognosis in African American and Caucasian women.
This is a randomized Phase 3 study to determine whether treatment with vaccinia virus based immunotherapy (Pexa-Vec) followed by sorafenib increases survival compared to treatment with sorafenib in patients with advanced hepatocellular carcinoma who have not received prior systemic therapy.
The purpose of this study is to compare Pembrolizumab vs. Pembrolizumab plus standard chemotherapy vs. standard chemotherapy alone in patients with Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma. (Clinicaltrials.gov ID#: NCT02494583)
This is an observational study to collect information on how relapsed multiple myeloma is managed in the United States from both a physician and patient perspective.
This randomized phase III trial studies how well doxorubicin hydrochloride and cyclophosphamide followed by paclitaxel with or without carboplatin work in treating patients with triple-negative breast cancer. (Clinicaltrials.gov ID#:NCT02488967)
The primary aim of the study is to determine the microbiological environment of the peritoneal tissues of patients undergoing cytoreductive surgery with intraoperative hyperthermic chemotherapy for appendix cancer with peritoneal spread.
This trial compares olaparib versus placebo as adjuvant treatment in patients with BRCA1 or BRCA2 mutations and triple negative breast cancer (ClinicalTrials.gov ID#: NCT02032823)
The purpose of this phase II trial is to determine the toxicity and post-operative complications related to cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) as an initial treatment option for patients with ovarian, fallopian tube, or primary peritoneal cancers and its impact on quality of life. Subjects will be randomized to one of two treatment groups: CRS with HIPEC followed by combination chemotherapy, carboplatin and paclitaxel, or CRS only followed by combination chemotherapy carboplatin and paclitaxel.
Protocol Title and ClinicalTrials ID#:
A phase II randomized study: Outcomes after cytoreductive surgery (CRS) with or without carboplatin hyperthermic intraperitoneal chemotherapy (HIPEC) followed by systemic chemotherapy with carboplatin and paclitaxel as initial treatment of ovarian, fallopian tube, and primary peritoneal cancer. NCT02124421
The objective of this study is to collect patient specimens prospectively (tumor, blood, vaginal swab, and urine sample) from benign, high risk, and malignant surgeries in order to develop diagnostic biomarkers and targeted anticancer agents for gynecologic tumors. http://lifegenedna.com/
This study is a phase II, open label, historical controlled study to determine the impact of antibiotic therapy on the disease progression and overall survival of the patients with Pseudomyxoma Peritonei (PMP). The study will examine the use of the antibiotic PREVPAC, in patients undergoing CRS/HIPEC for appendiceal neoplasms with peritoneal dissemination and its effect on patient outcomes and survival. (ClinicalTrials.gov ID#: NCT02387203)
This is a study to define the pathological staging for appendiceal neoplasms by examining mutations of the genetic makeup of tumor tissue and to analyze prognostic factors associated with various stages of appendiceal cancer with peritoneal dissemination.
The purpose of this study is to evaluate Niraparib in patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have received three or four previous chemotherapy regimens. (Clinicaltrials.gov ID#: NCT02354586)
This is a phase III trial for patients with Stage III unresectable non-small cell lung cancer, to determine how well nivolumab works after patients have received thoracic radiation and cisplatin and etoposide chemotherapy. (Clinicaltrials.gov ID#: NCT02768558)
The purpose for the study is to learn whether alpelisib, when added to fulvestrant, helps to reduce the growth of breast cancer cells in people with hormone receptor-positive, HER2-negative advanced breast cancer. (Clinicaltrials.gov ID#: NCT02437318)
This randomized phase III trial is studying how well giving hormone therapy together with or without everolimus works in treating patients with high-risk, hormone receptor-positive, HER2-negative breast cancer. (ClinicalTrials.gov ID#: NCT01674140)
This is a Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma (Clinicaltrials.gov ID#: NCT02506153).
This is a phase III randomized trial evaluate the efficacy and safety of pembrolizumab for women with triple-negative breast cancer who have residual invasive cancer or positive lymph nodes after neoadjuvant chemotherapy. (Clinicaltrials.gov ID#: NCT02954874)
This is an observational study for women who are receiving Intraoperative Radiation Therapy (IORT) following breast-conserving surgery. (ClinicalTrials.gov ID#: NCT01570998)
This study involves storing specimens from CRS/HIPEC patients with advanced colorectal, gastric, small bowel, primary peritoneal, ovarian cancers, peritoneal mesothelioma, and sarcomas. The purpose is to collect, maintain, and store tissues specimens from CRS/HIPEC and clinical data for future research. The collection of clinical data and outcomes from CRS/HIPEC for advanced intra-abdominal cancers will be used to refine future treatment protocols and enhance patient care.
The purpose of this research study is to evaluate effectiveness and safety of the combination of ublituximab and TGR-1202 is in comparison to the combination of Obinutuzumab and Chlorambucil, as well as in comparison to ublituximab and TGR-1202 when used alone. (ClinicalTrials.gov ID#: NCT02612311)
Paramount to the mission of the Sisters is the Mercy Cross.
Inspiring stories of Mercy Medical Center patients overcoming tough diagnoses and beating the odds.